Opthea Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Fred Guerard

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	24.9%
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	1.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Fred Guerard en comparación con los beneficios de Opthea?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	US$1m	US$373k	-US$220m

Compensación vs. Mercado: La compensación total de Fred($USD1.50M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.03M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Fred con los resultados de la empresa.

CEO

Fred Guerard (52 yo)

1.1yrs

Permanencia

US$1,496,440

Compensación

Dr. Frederic Guerard, also known as Fred, Pharm. D., M.S., is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at LENZ Therapeutics, Inc. since September 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Frederic Guerard	Chief Executive Officer	1.1yrs	US$1.50m	sin datos
Megan Baldwin	Founder & Chief Innovation Officer	no data	US$1.36m	0.016% € 73.7k
Karen Adams	VP of Finance & Company Secretary	3.4yrs	US$466.17k	0% € 0
Thomas Reilly	Chief Financial Officer	less than a year	sin datos	sin datos
Kevin Bitter	VP of Strategy & Corporate Development	no data	sin datos	sin datos
Anand Sundaram	Vice President Marketing	less than a year	sin datos	sin datos
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	sin datos	sin datos
Julie Clark	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos
Arshad Khanani	Chief Medical Advisor & Chairman of Medical Advisory Board	less than a year	sin datos	sin datos
Jen Watts	VP Global Clinical Operations	less than a year	sin datos	sin datos
Dayong Li	Senior VP	less than a year	sin datos	sin datos
Mike Campbell	Chief Commercial Officer	less than a year	sin datos	sin datos

0.5yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de UKJ no se considera experimentado ( 0.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Arshad Khanani	Chief Medical Advisor & Chairman of Medical Advisory Board	less than a year	sin datos	sin datos
Jeremy Levin	Chairperson	4.1yrs	US$309.43k	0.0051% € 23.8k
Quinton Oswald	Independence Non-Executive Director	2.6yrs	US$135.81k	sin datos
Julia Haller	Independent Non-Executive Director	3.4yrs	US$170.25k	sin datos
Frank Holz	Member of Medical Advisory Board	less than a year	sin datos	sin datos
Lawrence Gozlan	Independent Non-Executive Director	4.3yrs	US$790.52k	0.15% € 708.8k
Sujal Shah	Independent Non-Executive Director	less than a year	US$16.72k	sin datos
Anshul Thakral	Non-Executive Director	1.4yrs	US$103.72k	sin datos
Susan Orr	Independent Non-Executive Director	2.6yrs	US$130.26k	sin datos
Andrew Chang	Member of Medical Advisory Board	less than a year	sin datos	sin datos
Anat Loewenstein	Member of Medical Advisory Board	less than a year	sin datos	sin datos
Patricio Schlottmann	Member of Medical Advisory Board	less than a year	sin datos	sin datos

1.1yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de UKJ no se considera experimentada (1.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Opthea Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Opthea Limited Announces Board Changes

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Opthea Limited Announces Executive Changes

Opthea Limited Announces Board Appointments

Less than half of directors are independent

Recent updates

Opthea Limited Announces Board Changes

Opthea Limited, Annual General Meeting, Nov 15, 2024

Opthea Limited Appoint Executives

Forecast to breakeven in 2027

Opthea Limited Announces Executive Changes

New minor risk - Profitability

Full year 2024 earnings released: US$0.34 loss per share (vs US$0.32 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

New major risk - Financial position

Less than half of directors are independent

Opthea Limited Announces Board Changes

Forecast to breakeven in 2026

Founder recently sold €1.3m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.14 loss in FY 2021)

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: €1.03

New 90-day low: €1.19

New 90-day low: €1.26

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

New 90-day high: €1.74

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

New 90-day high - €1.66

Opthea Limited(ASX:OPT) dropped from S&P/ASX Emerging Companies Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo